Active ingredientVadadustatCat. No. P-V002-001CAS 1000025-07-9Family · Pharmaceutical analytical standards
Vadadustat
An oral inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase, used for anaemia of chronic kidney disease in patients on dialysis; it was approved in the European Union in 2023 and in the United States in 2024. This family brings together the active ingredient and labelled standards.
Did you know?It tricks the body by mimicking its natural response to a lack of oxygen, as happens at high altitude: the body then makes more of its own erythropoietin and uses iron better.
Go to the active ingredient →Active ingredientVadadustatCat. No. P-V002-001CAS 1000025-07-9
Isotopically labelledVadadustat-d5Cat. No. P-V002-002CAS 2229917-78-4No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.